Introduction: The aim of this study was to identify drivers of preference for growth hormone deficiency (GHD) treatment in French children, and their caregivers, and to quantify the relative importance of different aspects of treatment modalities using a discrete choice experiment (DCE). Materials and Methods: Attributes characterizing GHD treatment modalities were identified through a literature review, qualitative interviews, and focus groups with children, adolescents, and caregivers. A DCE questionnaire of 12 choice tasks was administered online to four groups of participants: autonomous adolescents (12–18 years), nonautonomous adolescent/caregiver dyads, caregivers of nonautonomous children (3–11 years), and autonomous children/caregiver dyads. The survey was pilot tested. A multinomial logit model with random effects was used to estimate preference weights for all attribute levels. Results: Frequency of administration, injection pain, dose setting, type of device, storage, and device reusability were selected as DCE attributes following the qualitative research phase and a pilot study. A total of 105 patients were represented in the DCE survey. Frequency of administration and injection pain were the attributes with the greatest influence on respondents’ preferences and had similar importance. Weekly administration was significantly preferred over daily administration by all groups of participants. Respondents’ choices were also significantly influenced by the type of device, dose setting, and device reusability. Conclusion: Children with GHD and their caregivers prefer a less frequent injection schedule and lower injection pain. Both aspects of treatment modalities are important to consider in treatment decisions to alleviate the daily burden for GHD patients and their families and potentially enhance treatment adherence.

2.
Amereller
F
,
Schilbach
K
,
Schopohl
J
,
Störmann
S
.
Adherence, attitudes and beliefs of growth hormone deficient patients: a questionnaire-based cohort study
.
Exp Clin Endocrinol Diabetes
.
2021
;
129
(
2
):
112
7
. .
3.
McNamara
M
,
Turner-Bowker
DM
,
Westhead
H
,
Yaworsky
A
,
Palladino
A
,
Gross
H
,
.
Factors driving patient preferences for Growth Hormone Deficiency (GHD) injection regimen and injection device features: a discrete choice experiment
.
Patient Prefer Adherence
.
2020
;
14
(
14
):
781
93
. .
4.
Brod
M
,
Højbjerre
L
,
Alolga
SL
,
Beck
JF
,
Wilkinson
L
,
Rasmussen
MH
.
Understanding treatment burden for children treated for growth hormone deficiency
.
Patient
.
2017
;
10
(
5
):
653
66
. .
5.
Loftus
J
,
Chen
Y
,
Alvir
JMJ
,
Chi
L
,
Dasgupta
S
,
Gupta
A
,
.
Suboptimal adherence to daily growth hormone in a US real-world study: an unmet need in the treatment of pediatric growth hormone deficiency
.
Curr Med Res Opin
.
2021
;
37
(
12
):
2141
50
. .
6.
Farfel
A
,
Shalitin
S
,
Morag
N
,
Meyerovitch
J
.
Long-term adherence to growth hormone therapy in a large health maintenance organization cohort
.
Growth Horm IGF Res
.
2019
;
44
:
1
5
. .
7.
Kremidas
D
,
Wisniewski
T
,
Divino
VM
,
Bala
K
,
Olsen
M
,
Germak
J
,
.
Administration burden associated with recombinant human growth hormone treatment: perspectives of patients and caregivers
.
J Pediatr Nurs
.
2013
;
28
(
1
):
55
63
. .
8.
Marini
MG
,
Chesi
P
,
Mazzanti
L
,
Guazzarotti
L
,
Toni
TD
,
Salerno
MC
,
.
Stories of experiences of care for growth hormone deficiency: the CRESCERE project
.
Future Sci OA
.
2016
;
2
(
1
):
FSO82
. .
9.
Chachoua
L
,
Dabbous
M
,
François
C
,
Dussart
C
,
Aballéa
S
,
Toumi
M
.
Use of patient preference information in benefit-risk assessment, health technology assessment, and pricing and reimbursement decisions: a systematic literature review of attempts and initiatives
.
Front Med
.
2020
;
7
:
543046
. .
10.
van Overbeeke
E
,
Whichello
C
,
Janssens
R
,
Veldwijk
J
,
Cleemput
I
,
Simoens
S
,
.
Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review
.
Drug Discov Today
.
2019
;
24
(
1
):
57
68
. .
11.
The PREFER consortium
.
REFER Recommendations: why, when and how to assess and use patient preferences in medical product decision-making
.
2022
.
12.
Recommendations for the methodology and visualisation techniques to be used in the assessment of benefit and risk of medicines: PROTECT, the pharmacoepidemiological research on outcomes of therapeutics by a European Consortium
.
2013
. Available from: http://www.imi-protect.eu/documents/HughesetalRecommendationsforthemethodologyandvisualisationtechniquestobeusedintheassessmento.pdf.
13.
Patient preference information: submission, review in PMAs, HDE applications, and de Novo requests, and inclusion in device labeling: CDRH, the US Food and Drug Administration (FDA) center for devices and radiological Health
.
2015
. Available from: http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM446680.pdf.
14.
Reed Johnson
F
,
Lancsar
E
,
Marshall
D
,
Kilambi
V
,
Mühlbacher
A
,
Regier
DA
,
.
Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force
.
Value Health
.
2013
;
16
(
1
):
3
13
. .
15.
Determann
D
,
Lambooij
MS
,
Steyerberg
EW
,
de Bekker-Grob
EW
,
de Wit
GA
.
Impact of survey administration mode on the results of a health-related discrete choice experiment: online and paper comparison
.
Value Health
.
2017
;
20
(
7
):
953
60
. .
16.
Tanaka
T
,
Sato
T
,
Yuasa
A
,
Akiyama
T
,
Tawseef
A
.
Patient preferences for growth hormone treatment in Japanese children
.
Pediatr Int
.
2021
;
63
(
10
):
1185
91
. .
17.
Loftus
J
,
Lamoureux
RE
,
Yaworsky
A
,
Shields
AL
,
Morrissey
L
,
Kelly
M
,
.
Caregiver burden in daily human growth hormone injections for children
.
Value Health
.
2017
;
20
(
9
):
A758
. .
18.
Cutfield
WS
,
Derraik
JG
,
Gunn
AJ
,
Reid
K
,
Delany
T
,
Robinson
E
,
.
Non-compliance with growth hormone treatment in children is common and impairs linear growth
.
PLoS One
.
2011
;
6
(
1
):
e16223
. .
19.
Hughes
IP
,
Choong
C
,
Rath
S
,
Atkinson
H
,
Cotterill
A
,
Cutfield
W
,
.
Early cessation and non-response are important and possibly related problems in growth hormone therapy: an OZGROW analysis
.
Growth Horm IGF Res
.
2016
;
29
:
63
70
. .
20.
Joosten
EAG
,
DeFuentes-Merillas
L
,
De Weert
GH
,
Sensky
T
,
Van Der Staak
CPF
,
de Jong
CAJ
.
Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status
.
Psychother Psychosom
.
2008
;
77
(
4
):
219
26
. .
21.
Ito
H
.
What should we do to improve patients’ adherence
.
J Exp Clin Med
.
2013
;
5
(
4
):
127
30
. .
22.
Johnson
R
,
Orme
B
.
Getting the most from CBC. Sequim: sawtooth software research paper series
.
Sawtooth Software
;
2003
.
You do not currently have access to this content.